Get the Stockscreener App
1,116.29
0.60%
-6.7091
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,116.29, with a volume of 846.12K.
It is down -0.60% in the last 24 hours and down -8.13% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,123.00
Open:
$1129.405
24h Volume:
846.12K
Relative Volume:
0.31
Market Cap:
$994.78B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
40.18
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-2.88%
1M Performance:
-8.13%
6M Performance:
+11.64%
1Y Performance:
+47.59%
1-Day Range:
$1,114.31
$1,131.44
1-Week Range:
$1,113.55
$1,138.79
52-Week Range:
$712.05
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,116.03 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.80 | 641.88B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.89 | 450.61B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.38 | 357.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.19 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - theglobeandmail.com
Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report - Benzinga
Can Eli Lilly (NYSE:LLY) Keep Its Obesity Pipeline Growing? - Kalkine Media
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - Zacks Investment Research
The Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo continue prescription climb - fiercepharma.com
Eli Lilly Stock (LLY) in Focus as Company Completes $3.8 Billion AtaiBeckley Purchase - TipRanks
Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline - citybiz
Eli Lilly completes acquisition of AtaiBeckley, initiates delisting from Nasdaq - Investing.com
Eli Lilly (NYSE: LLY) now owns all of AtaiBeckley (NASDAQ: ATAI) - stocktitan.net
Lilly completes acquisition of AtaiBeckley for mental health drugs - Investing.com
Lilly completes acquisition of AtaiBeckley for mental health drugs By Investing.com - Investing.com UK
Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup - ChartMill
Lilly doubles down on women's health strategy - briefs.co
Why Eli Lilly (NYSE:LLY) Draws Notice As Metabolic-Disease Pipeline Advances - Kalkine Media
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive? - Trefis
Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health - Bloomberg.com
Got $10,000? Eli Lilly vs. Nvidia: The Better Buy For 2026 - 24/7 Wall St.
Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy? - 24/7 Wall St.
$Eli Lilly and Co (LLY.US)$ - moomoo.com
Eli Lilly (NYSE:LLY): Is This Run Still Undervalued? - Kalkine Media
HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating - marketscreener.com
Why Is Eli Lilly (NYSE:LLY) Drawing Market Attention? - Kalkine Media
The Zacks Analyst Blog Highlights Eli Lilly, Palo Alto, Texas Instruments and Stratus Properties - Yahoo Finance
Calif. Judge Hands Eli Lilly Mixed Bag In Compound Drug Row - Law360
Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments - Yahoo Finance Singapore
Eli Lilly investing hundreds of thousands of dollars to bolster Kenosha manufacturing workforce - The Business Journals
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks - Yahoo Finance
BMO reiterates Eli Lilly stock rating on incretin growth outlook - Investing.com
BMO reiterates Eli Lilly stock rating on incretin growth outlook By Investing.com - Investing.com UK
Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 - The Motley Fool
What Is Shaping Interest in Eli Lilly Stock? (NYSE:LLY) - Kalkine Media
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly lawsuit against weight-loss drug seller gets another shave - Courthouse News
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years - Benzinga
Here's Why Eli Lilly (LLY) Fell More Than Broader Market - Yahoo Finance
Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline - Kalkine Media
ELI LILLY Executive Vice President Eric Dozier Retains 14,239 Shares Following Gift Transaction - Kalkine Media
Eli Lilly scholarship backs Gateway manufacturing students - Kenosha News
Lilly fighting black market for its next obesity drug - The Indiana Lawyer
Eli Lilly (NYSE:LLY): Can New FDA Approvals Fuel Growth? - Kalkine Media
Why Is Eli Lilly Stock Falling Tuesday? - Benzinga
Lilly invests SGD $42M in new Digital Health Hub in Singapore - Singapore Economic Development Board (EDB)
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? - Yahoo Finance
Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 14.46% Upside in the Healthcare Giant - DirectorsTalk Interviews
Eli Lilly expands US pharmaceutical manufacturing with over US$50bn investment - Scientist Live
Eli Lilly’s $100B incretin opportunity: Is more upside coming? - Investing.com
Eli Lilly (LLY) Posts 52 Week Trial Data, Is The Stock Trading At A Discount? - simplywall.st
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years - The Motley Fool
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):